Which is the best route of administration for cell therapy in experimental model of small-for size syndrome in rats?

PURPOSE: To evaluate which is the best route of administration for cell therapy in experimental rat model of small-for size syndrome. METHODS: A total of 40 rats underwent partial hepatectomy (70%) that induces the small-for-size syndrome and were divided into four groups of route administration: intravenous, intraperitoneal, enteral and tracheal. The small-for-size syndrome model was designed with extended partial hepatectomy (70%). The animals were divided into four groups of routes administration: intravenous (n=10) - intravenously through the dorsal vein of the penis; intraperitoneal (n=10) - intraperitoneally in the abdominal cavity; enteral (n=10) - oroenteral with the placement of a number 4 urethral probe and maintained at third duodenal portion; tracheal (n=10) - after tracheal intubation. We track the animals and monitor them for 21 days; during this follow-up we evaluated the result of cell therapy application tracking animals using ultrasound, radiography and PET-scan. Statistical analysis was performed using GraphPad Prism Software(r). Differences were considered significant with the p<0.05. Data are presented as the median and variation for continuous variables. Comparisons between groups were made using analysis of the imaging test by the researchers. RESULTS: All four groups underwent partial hepatectomy of 70% liver tissue targeting the same weight of resected liver. Initially the PET-scan tests showed similarity in administered cells by different routes. However, in few days the route of intravenous administration showed to be the most appropriated to lead cells to the liver followed by enteral. The tracheal and peritoneal routes were not as much successful for this goal. CONCLUSION: The intravenous route is the best one to cell therapy in experimental rat model of small-for size-syndrome. .

Antiproliferative and antimetastatic activity of DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate, in B16F10 melanoma

Melanoma causes 75% of skin cancer deaths mainly due to its high potential to progress to metastasis and by its recognized resistance to conventional therapies. Compound DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate, presents structural and biological similarity to curcumin, exhibiting properties such as potent antitumoral and antioxidant activities. In this work, the antitumoral and antiproliferative effects of this compound in in vitro assays with tumor and normal cell lines have been evaluated. Also evaluated was the in vivo antitumoral potential against B16F10 melanoma-bearing mice. Normal and tumor cells were treated with different concentrations of compound DM-1 and the cellular viability was determined by MTT colorimeter assay. The half maximal inhibitory concentration (IC50) found was 30 ìg/mL in B16F10 melanoma cells, while no toxic activity was verified against normal human fibroblastic cells. When DM-1 was administrated by intraperitoneal and endovenous routes to melanoma-bearing animals the survival rate increased by 40% when compared to the control group. Tumor load was reduced by 84% when administered via endovenous and by 54% via intraperitoneal. In conclusion, compound DM-1 acts as selective antitumoral agent inducing cytotoxicity in B16F10 melanoma cells, reducing the tumor load in the treated animals, as well as increasing the survival rate of the animal bearing this neoplasia.

Análise dos efeitos da soluçäo de fluoreto estanhoso associado ao flúor fosfato acidulado sobre a placa bacteriana e na quantidade de Streptococcus mutans em indivíduos de 21 a 23 anos de idade / Evaluation of the effects of a stannous fluoride mouthrinse associated to the acidulated phosphate fluoride on dental plaque and on salivary Streptococcus mutans in patients aged 21 to 23 years

O presente trabalho teve a finalidade de avaliar os efeitos de uma soluçäo de enxágüe contendo fluoreto estanhoso (SnF2) a l,64 por cento e flúor fosfato acidulado a 0,3l por cento sobre a placa bacteriana e na quantidade de Streptococcus mutans na saliva em indivíduos com idade variando entre 21 a 23 anos. Quinze voluntários utilizaram a soluçäo experimental uma vez ao dia, durante vinte três dias. Tanto o índice de placa como a análise salivar foram realizados antes e após a fase experimental, quando se observou que a utilizaçäo da soluçäo experimental propociou uma diminuiçäo significativa no índice de placa e na quantidade de Streptococcus mutans na saliva, levando os autores a concluir que este pode ser um método efetivo na prevençäo da cárie dentária, bem como de problemas periodontais